Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Garattini, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garattini, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:813-816, 2003
© 2003 European Society for Medical Oncology

Editorial

New approaches to cancer therapy

S. Garattini

Istituto di Ricerche Farmacologiche "Mario Negri", Via Eritrea 62, 20157 Milano, Italy

*E-mail: mapelli@marionegri.it

The first 150 words of the full text of this article appear below.

In the last decade there has been a decrease, for the first time in Europe, in the age-standardized mortality for all cancers [1], from 147 to 136 per 100 000 inhabitants per year. The reasons are many, and include preventive interventions, early diagnosis, changes in lifestyle (mostly giving up tobacco smoking) and better treatments, at least for some tumors [2]. However, with notable exceptions, pharmacological treatments are responsible for only a small fraction of cancer cures, although they are credited with an increase of survival in some cases [2]. Even the latest drugs on the market do not achieve the desired improvement considering the expectations generated by the advances in fundamental knowledge of cancer cell proliferation and dissemination [3].

To be of clinical interest a drug must provide measurable advantages to patients or to national health services. In other words, it should be . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?